S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE

S-3-(4-Fluorophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide, commonly known as S-1, is an experimental selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed by GTx, Inc. and the University of Tennessee, it was one of the first nonsteroidal SARMs to be characterized for its tissue-selective anabolic effects. S-1 acts as a potent agonist of the androgen receptor (AR), designed to promote muscle growth and bone density while minimizing the undesirable androgenic effects on reproductive organs such as the prostate. In preclinical models, S-1 has demonstrated the ability to increase lean body mass and physical activity. While it served as a critical proof-of-concept molecule in the development of the SARM class, its clinical development was largely superseded by more optimized analogs like andarine (S-4) and enobosarm (S-22). Potential therapeutic applications explored for this compound include the treatment of muscle-wasting diseases, sarcopenia, cachexia, and osteoporosis.

Other names

(2S)-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamideCAS 401900-41-2CAS401900-41-2CAS-401900-41-2